Search | Clinical Trials Finder

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Nutrient; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 1 Day to 6 Months
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sickle Cell Disease
Interventions: Hematopoietic Stem Cell Transplantation, CliniMACS, See intervention description; Procedure · Device · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 16 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Chronic Kidney Disease
Interventions: Educate and Engage, Educate and Engage Plus Kidney Supportive Care Program; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 65 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 25
States / cities: San Francisco, California • Washington D.C., District of Columbia • Canton, Georgia + 19 more

Conditions: Pulmonary Fibrosis
Interventions: N-acetylcysteine (NAC), Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 35 Years to 85 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 20 more

Conditions: Hemophilia A
Interventions: Advate (Low Dose), Advate (High Dose), BIVV001 (Low Dose), BIVV001 (High Dose); Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 4 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Ustekinumab IV, Placebo Infusion, Placebo SC, Ustekinumab SC, Concomitant Medication; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 12
States / cities: Huntsville, Alabama • Beverly Hills, California • Tampa, Florida + 9 more

Conditions: Adverse Drug Reaction
Interventions: Pharmacogenetic Intervention Arm (pharmacogenetic testing); Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 4,465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Systemic Lupus Erythematosus
Interventions: Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT), Plasmapheresis, Rabbit anti-thymocyte globulin, Methylprednisolone, Growth colony stimulating factor (G-CSF), Corticosteroids, Mycophenolate mofetil, Azathioprine, Intravenous immunoglobulin, Methotrexate, Rituximab, Leflunomide; Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 5
States / cities: La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more

Conditions: Colitis, Ulcerative
Interventions: Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C; Biological
Lead sponsor: Alimentiv Inc.; Other
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Ypsilanti, Michigan • New York, New York • Asheville, North Carolina + 1 more

Conditions: Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
Interventions: Not listed
Lead sponsor: Splice Bio; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 14
States / cities: San Diego, California • Aurora, Colorado • Gainesville, Florida + 10 more

Conditions: Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
Interventions: Sirolimus, MMF or Azathioprine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Year to 20 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Madera, California • San Francisco, California • Boston, Massachusetts + 2 more

Conditions: Concussion, Mild
Interventions: Nicotinamide Riboside, Matching placebo; Dietary Supplement · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA
Interventions: Anal Pap smear and HPV DNA testing; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 310 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Melanoma
Interventions: Trametinib (GSK1120212), GSK2141795; Drug
Lead sponsor: Adil Daud; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Cholesterol, HDL, Lipid Metabolism, Inborn Errors, Tangier Disease, LCAT Deficiency, Cholesteryl Ester Transfer Protein (CETP) Deficiency
Interventions: 3H-cholesterol bound to albumin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypercholesterolemia
Interventions: Bempedoic acid; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • West Covina, California • Boca Raton, Florida + 5 more

Conditions: Lung Transplant; Complications
Interventions: Tacrolimus Extended Release Oral Tablet [Envarsus], Tacrolimus, Mycophenolate Mofetil Hydrochloride, Prednisone, Azathioprine; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: COVID-19 Acute Respiratory Distress Syndrome
Interventions: Agilent Seahorse XF Cell Mito Stress Test; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Rheumatic Disease
Interventions: Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib; Drug · Biological
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Non Hodgkin Lymphoma
Interventions: UF-KURE19 CAR-T cells, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: David Wald; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Iowa City, Iowa • Cleveland, Ohio

Conditions: Sickle Cell Disease
Interventions: CD34 selected T-cell depleted allogeneic SCT; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 2 Years to 20 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more

Conditions: Sickle Cell Disease, Hemolytic Anemia
Interventions: Mitapivat; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dyslipidemia
Interventions: AZD0780, Ezetimibe, Rosuvastatin, Bempedoic Acid, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions: Liposomal Cyclosporine A, standard of care; Drug
Lead sponsor: Zambon SpA; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Search by objective public record fields.

Genetic Regulation of Surfactant Deficiency

Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound

Expanding and Promoting Alternative Care and kNowledge in Decision-making Trial

Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

Determination of the Optimal Treatment Target in Ulcerative Colitis

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation

Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes

Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls

Trametinib With GSK2141795 in BRAF Wild-type Melanoma

Mendelian Reverse Cholesterol Transport Study

A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

T-Cell Mitochondrial Respiration Response to Ketone Monoester Supplement in Healthy Volunteers and COVID-19

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)